Search

Displaying results 4241 - 4250 of 10000 in total
  1. Drug

    Coltuximab ravtansine

    go.drugbank.com/drugs/DB06342
    Investigational

    Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).

  2. Drug

    Chikungunya virus Senegal strain 37997 envelope protein E1

    go.drugbank.com/drugs/DB21767
    ApprovedInvestigational

    One of three components of a recombinant Chikungunya virus vaccine called Vimkunya.

  3. Drug

    TRC093

    go.drugbank.com/drugs/DB06356
    Investigational

    TRC093 is a recombinant humanized IgG1k monoclonal antibody.

  4. Drug

    AZD-2836

    go.drugbank.com/drugs/DB06031
    Investigational

    AZD-2836 is an inhibitor of the nonstructural protein 5A (NS5A).[A264853] The drug is being investigated for treatment of hepatitis C because AZD-2836 has in vitro anti-HCV activity.[A264858]

    Synonyms: 6-(3,4-Dimethoxyphenyl)-N-[4-(1H-1,2,4-triazol-1-yl)phenyl]-4-quinazolinamine
  5. Drug

    Sulfapyridine

    go.drugbank.com/drugs/DB00891
    ApprovedWithdrawn

    Antibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.

    Synonyms: N-2-Pyridylsulfanilamide, N(1)-Pyridylsulfanilamide
  6. Drug

    Phenobarbital

    go.drugbank.com/drugs/DB01174
    ApprovedInvestigational

    It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.

  7. Drug

    Aluminium

    go.drugbank.com/drugs/DB01370
    ApprovedInvestigationalWithdrawn

    A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.

  8. Drug

    Nimesulide

    go.drugbank.com/drugs/DB04743
    ApprovedWithdrawn

    Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries. … Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old.

    Products: NI-M-DOL® (NIMESULIDA SUSPENSION), MESULID SUSPENSION PARA ADMINISTRACIÓN EN GOTAS
  9. Drug

    DDP-200

    go.drugbank.com/drugs/DB05919
    Experimental

    DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia

  10. Drug

    ABX-PTH

    go.drugbank.com/drugs/DB05883
    Experimental

    ABX-PTH is a fully human monoclonal antibody generated by Abgenix's technology platform.